For the period (end-July 3), revenue grew 34% to $9.27 billion, compared with $6.92 billion in the second quarter of 2020.

During this period, the company launched a new clinical and commercial cell therapy manufacturing facility at the University of California, San Francisco, as well as research collaboration to support the scale-up of studies and research in metabolomics. Also, Thermo Fisher brought additional capacity online to support vaccine and therapy production globally and expanded the production of laboratory plastics in North America and Europe.

After the quarter closed, the company opened a new plasmid DNA facility in California. It was opened to meet the demand for DNA-based therapies and mRNA-based vaccines, Thermo Fisher said.

Thermo Fisher commits to net-zero emissions by 2050
Thermo Fisher Scientific said it is committed to achieving net-zero carbon emissions by 2050.

Thermo Fisher announces new suite of assays
Thermo Fisher Scientific announced a new suite of Ion Torrent Oncomine immune repertoire assays designed to detect potentially malignant clones of T cells...

Thermo Fisher opens cGMP plasmid DNA manufacturing facility in Calif.
Thermo Fisher Scientific announced it has officially opened its new current good manufacturing practice (cGMP) plasmid DNA manufacturing facility in Carlsbad,...

Thermo Fisher Scientific upgrades Quick to Clinic
Thermo Fisher Scientific is showcasing a new version of its Quick to Clinic service for biologic drug developers at the BIO Digital 2021 conference, which...

Thermo Fisher announces Q1 revenue increase
Thermo Fisher Scientific said that its efforts to help scale vaccine production and support diagnostic testing globally during the COVID-19 pandemic were...